Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results

PURPOSE: Oxymetazoline 0.1% is a novel ophthalmic agent for the treatment of acquired blepharoptosis in adults that has been shown to improve upper eyelid elevation and superior visual field deficits. This analysis characterized the rapid onset of upper eyelid elevation with once-daily oxymetazoline...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacharach, Jason, Wirta, David L, Smyth-Medina, Robert, Korenfeld, Michael S, Kannarr, Shane R, Foster, Shane, J Jaros, Mark, Slonim, Charles B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240850/
https://www.ncbi.nlm.nih.gov/pubmed/34211263
http://dx.doi.org/10.2147/OPTH.S306155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240850/
https://www.ncbi.nlm.nih.gov/pubmed/34211263
http://dx.doi.org/10.2147/OPTH.S306155

Ejemplares similares